Novel Cardiovascular Therapeutics Summit 2017 San Francisco, California, USA 28 February - 1 March, 2017

Description:
The Novel Cardiovascular Therapeutics Summit reveals how the latest developments in the genetic and molecular understanding of cardiovascular disease, heart failure and cardiomyopathy are being translated into new pharmacological therapies in the clinic.

From the state of the art on cardiovascular drug development, to innovative therapeutic approaches, precision medicine and advancements in clinical trial methodologies, this meeting combines cutting edge science with a practical evaluation of case studies.

The agenda has been designed with insight from academicians and biopharmaceutical leaders in cardiovascular clinical research to help you tackle your major preclinical and clinical challenges to achieve safer, faster and more cost-effective cardiovascular drug development.

This is a great opportunity to interact with fellow peers in frank discussions that will ensure that you leave with the tools and ideas to advance your research and help shape the future of cardiovascular therapies.

Price
Industry - Earlybird (Register by 27 January 2017): USD 2399
Industry - Standard: USD 2699
Academic - Earlybird (Register by 27 January 2017): USD 1399
Academic - Standard: USD 1599

Speakers: Matthew T Roe (DCRI), Joerg Koglin PhD (Merck), Brian A Ference (Wayne State University), Mark C Kowala PhD (Eli Lilly & Company)